Endoscopic screening for gastrointestinal cancers

Precise estimates of the magnitude of benefits and harms of endoscopic screening for cancer are a prerequisite for informed decision making for or against participation in screening for individuals in the target population.

Photo: Colourbox

In the paper Do’s and don’ts in evaluation of endoscopic screening for gastrointestinal cancers published online first in the journal Endoscopy on Sept 21st, Michael Bretthauer and co-workers from the Clinical Effectiveness Research group outline the most common pitfalls in the evaluation of screening and offer recommendations for future studies.

Latest publications

Berg et al. 2019. Gene expression profiles of CMS2-epithelial/canonical colorectal cancers are largely driven by DNA copy number gains. Oncogene [Epub ahead of print] Sveen A, Kopetz S, Lothe RA. 2019. Biomarker-guided therapy for colorectal cancer: strength in complexity. Nat. Rev. Clin. Oncol. [Epub ahead of print] Marcuello et al. 2019. Circulating biomarkers for early detection and clinical management of colorectal cancer. Mol. Asp. Med. [Epub ahead of print] Smeby et al. 2019. Transcriptional and functional consequences of TP53 splice mutations in colorectal cancer. Oncogenesis 8(6): 35 Kryeziu et al., 2019. Combination therapies with HSP90 inhibitors against colorectal cancer. BBA Reviews on Cancer, 1871(2): 240-247 All publications